Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at TD Cowen in a research report issued on Tuesday, Benzinga reports.
A number of other equities research analysts have also weighed in on FUSN. Raymond James reaffirmed a “market perform” rating on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Truist Financial reiterated a “hold” rating and set a $21.00 price objective (up from $11.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Bloom Burton downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. B. Riley downgraded shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $13.00 to $23.00 in a research note on Wednesday, March 20th. Finally, Leerink Partnrs downgraded shares of Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Fusion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $20.25.
Check Out Our Latest Analysis on Fusion Pharmaceuticals
Fusion Pharmaceuticals Stock Performance
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. Sell-side analysts anticipate that Fusion Pharmaceuticals will post -1.46 EPS for the current year.
Hedge Funds Weigh In On Fusion Pharmaceuticals
Several hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new position in shares of Fusion Pharmaceuticals in the 4th quarter worth approximately $7,154,000. Goldman Sachs Group Inc. purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $145,000. Chartwell Investment Partners LLC acquired a new position in Fusion Pharmaceuticals in the 4th quarter worth approximately $480,000. Pier Capital LLC acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $2,663,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $1,656,000. Institutional investors and hedge funds own 72.85% of the company’s stock.
Fusion Pharmaceuticals Company Profile
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.
Featured Articles
- Five stocks we like better than Fusion Pharmaceuticals
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- United Airlines Soars on Earnings Beat
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Stock Analyst Ratings and Canadian Analyst Ratings
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.